Neurona Therapeutics Revenue and Competitors

Location

#1594

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Neurona Therapeutics's estimated annual revenue is currently $5.1M per year.(i)
  • Neurona Therapeutics's estimated revenue per employee is $77,500
  • Neurona Therapeutics's total funding is $316M.

Employee Data

  • Neurona Therapeutics has 66 Employees.(i)
  • Neurona Therapeutics grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Neurona Therapeutics?

Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four leading-edge neuroscientists and stem cell pioneers at The University of California, San Francisco. We are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Our initial aim is to generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, we believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Our talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

keywords:N/A

$316M

Total Funding

66

Number of Employees

$5.1M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neurona Therapeutics News

2022-03-30 - Neurona Therapeutics to Present at the Locust Walk Stem Cell ...

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell...

2021-06-22 - Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders

Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total proceeds raised to date to $135 million SAN FRANCISCO, June 22, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics Inc ...

2015-12-01 - Neurona Therapeutics Raises $23.5M in Series A Financing

Neurona Therapeutics Inc., a South San Francisco, CA-based biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, launched with a $23.5m Series A financing. The round was led by The Column Group. Led by Tim Kutzkey, interim Chief Ex ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.3M66-3%$80.9M
#2
$24M66-4%$1.3B
#3
$9.3M693%N/A
#4
$17.6M706%N/A
#5
$15M720%N/A